EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?

Laura Calabrese, Martina D'Onghia iD, Laura Lazzeri, Giovanni Rubegni, Elisa Cinotti iD

Journal of Personalized Medicine · 22.07.2024 · 14 (7) · 775

DOI: 10.3390/jpm14070775 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 22.07.2024. Verfasst von Laura Calabrese und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) is an immune-mediated skin disorder with a chronic-relapsing course and a multifactorial pathogenesis. In contrast to the traditional concept of AD as solely a type 2 immune-activated disease, new findings highlight the disease as highly heterogeneous, as it can be classified into variable phenotypes based on clinical/epidemiological or molecular parameters. For many years, the only therapeutic option for moderate–severe AD was traditional immunosuppressive drugs. Recently, the area of systemic therapy of AD has significantly flourished, and many new substances are now marketed, licensed, or in the last step of clinical development. Biological agents and small molecules have enriched the therapeutic armamentarium of moderate-to-severe AD, such as dupilumab, tralokinumab, lebrikizumab (monoclonal antibodies targeting the IL-4/13 pathway), abrocitinib, upadacitinib, and baricitinib (JAK inhibitors). Indeed, the AD treatment paradigm is now split into two main approaches: targeting the IL-4/13 axis or the JAK/STAT pathway. Both approaches are valid and have strong evidence of preclinical and clinical efficacy. Therefore, the choice between the two can often be difficult and represents a major challenge for dermatologists. Indeed, several important factors must be taken into account, such as the heterogeneity of AD and its classification in phenotypes, patients’ comorbidities, age, and personal preferences. The aim of our review is to provide an overview of the clinical and molecular heterogeneities of AD and to explore the factors and parameters that, in clinical practice, may help inform clinical decision-making.

Schlagwörter

Stichwörter der Autor:innen

JAK inhibitorsanti IL-4/13 monoclonal antibodiesatopic dermatitispersonalized medicine

Autor:innen und Institutionen

  • Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy.
  • Institute of Dermatology, Catholic University of the Sacred Heart, 00168 Rome, Italy.

ORCID-Profile: Martina D'Onghia, Elisa Cinotti

Zitieren

APA

Calabrese, L., D'Onghia, M., Lazzeri, L., Rubegni, G., & Cinotti, E. (2024). Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?. Journal of Personalized Medicine, 14(7), 775. https://doi.org/10.3390/jpm14070775

Vancouver

Calabrese L, D'Onghia M, Lazzeri L, Rubegni G, Cinotti E. Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?. Journal of Personalized Medicine. 2024;14(7):775. doi:10.3390/jpm14070775

BibTeX
@article{Calabrese2024,
  author = {Calabrese, Laura and D'Onghia, Martina and Lazzeri, Laura and Rubegni, Giovanni and Cinotti, Elisa},
  title = {Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?},
  journal = {Journal of Personalized Medicine},
  year = {2024},
  volume = {14},
  number = {7},
  pages = {775},
  doi = {10.3390/jpm14070775}
}
Kostenlos starten →